Crossmark

Enhanced clinical decisions for management of benign prostatic hyperplasia using patient-reported outcomes: protocol for a prospective observational study

Crossref DOI link: https://doi.org/10.1186/s12894-024-01500-0

Published Online: 2024-05-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Glaser, Alexander P.

Smith, Abigail R.

Maglaque, Dacey

Helfand, Brian T.

Mohamed, Rowida

An, Hosanna

Marquez, Melissa

Talaty, Pooja

Carolan, Padraig

Geller, Aaron M.

Farina, Francesca R.

Jensen, Sally E.

Griffith, James W.
Funding

Funding for this research was provided by:

National Institutes of Health (R01 DK130963-01A1, R01 DK130963-01A1, R01 DK130963-01A1, R01 DK130963-01A1, R01 DK130963-01A1, R01 DK130963-01A1, R01 DK130963-01A1, R01 DK130963-01A1, R01 DK130963-01A1, R01 DK130963-01A1, R01 DK130963-01A1, R01 DK130963-01A1, R01 DK130963-01A1)
License Information

Text and Data Mining valid from 2024-05-21

Version of Record valid from 2024-05-21
More Information

Article History

Received: 22 April 2024

Accepted: 15 May 2024

First Online: 21 May 2024

Declarations

:

: This study was approved by the Institutional Review Boards of Northwestern University (IRB STU00217126), which served as the single IRB of record. This study is registered in ClinicalTrials.gov (NCT05898932). A coordinator will contact patients by phone or in person to describe the study and obtain informed consent, which will be documented using the Research Electronic Data Capture System (REDCap).

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below